vs
Side-by-side financial comparison of Falcon's Beyond Global, Inc. (FBYD) and Protalix BioTherapeutics, Inc. (PLX). Click either name above to swap in a different company.
Protalix BioTherapeutics, Inc. is the larger business by last-quarter revenue ($9.1M vs $6.6M, roughly 1.4× Falcon's Beyond Global, Inc.). Falcon's Beyond Global, Inc. runs the higher net margin — -4.5% vs -60.3%, a 55.8% gap on every dollar of revenue. On growth, Falcon's Beyond Global, Inc. posted the faster year-over-year revenue change (383.5% vs -49.9%). Protalix BioTherapeutics, Inc. produced more free cash flow last quarter ($1.6M vs $-4.3M). Over the past eight quarters, Falcon's Beyond Global, Inc.'s revenue compounded faster (108.4% CAGR vs -6.7%).
500 Global is an early-stage venture fund and seed accelerator founded in 2010 by Dave McClure and Christine Tsai. The fund admitted a first "class" of twelve startups to its incubator office in Mountain View, California in February 2011. They expanded to a second class of 21 in June 2011 and a third class of 34 in October 2011. 500 Global has $2.3 billion in assets under management (AUM) as of March 2024.
Protalix BioTherapeutics is an Israeli pharmaceutical company that manufactures a plant-based enzyme, taliglucerase alfa, which has received U.S. Food and Drug Administration approval for the treatment of Gaucher disease.
FBYD vs PLX — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $6.6M | $9.1M |
| Net Profit | $-296.0K | $-5.5M |
| Gross Margin | — | 49.4% |
| Operating Margin | -30.9% | -51.1% |
| Net Margin | -4.5% | -60.3% |
| Revenue YoY | 383.5% | -49.9% |
| Net Profit YoY | 97.5% | -184.8% |
| EPS (diluted) | $-0.01 | $-0.06 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $6.6M | $9.1M | ||
| Q3 25 | $4.1M | $17.9M | ||
| Q2 25 | $2.5M | $15.7M | ||
| Q1 25 | $1.7M | $10.1M | ||
| Q4 24 | $1.4M | $18.2M | ||
| Q3 24 | $2.1M | $18.0M | ||
| Q2 24 | $1.8M | $13.5M | ||
| Q1 24 | $1.5M | — |
| Q4 25 | $-296.0K | $-5.5M | ||
| Q3 25 | $-10.4M | $2.4M | ||
| Q2 25 | $25.1M | $164.0K | ||
| Q1 25 | $-8.1M | $-3.6M | ||
| Q4 24 | $-11.9M | $6.5M | ||
| Q3 24 | $39.3M | $3.2M | ||
| Q2 24 | $8.0M | $-2.2M | ||
| Q1 24 | $114.0M | — |
| Q4 25 | — | 49.4% | ||
| Q3 25 | — | 53.4% | ||
| Q2 25 | — | 62.5% | ||
| Q1 25 | — | 19.1% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 53.4% | ||
| Q2 24 | — | 29.8% | ||
| Q1 24 | — | — |
| Q4 25 | -30.9% | -51.1% | ||
| Q3 25 | -90.9% | 11.9% | ||
| Q2 25 | -53.0% | 7.5% | ||
| Q1 25 | -371.1% | -41.0% | ||
| Q4 24 | -335.6% | 39.6% | ||
| Q3 24 | -118.9% | 22.2% | ||
| Q2 24 | -195.9% | -18.0% | ||
| Q1 24 | -350.5% | — |
| Q4 25 | -4.5% | -60.3% | ||
| Q3 25 | -256.8% | 13.2% | ||
| Q2 25 | 985.2% | 1.0% | ||
| Q1 25 | -473.8% | -35.8% | ||
| Q4 24 | -871.7% | 35.6% | ||
| Q3 24 | 1899.5% | 18.0% | ||
| Q2 24 | 446.5% | -16.4% | ||
| Q1 24 | 7521.4% | — |
| Q4 25 | $-0.01 | $-0.06 | ||
| Q3 25 | $-0.13 | $0.03 | ||
| Q2 25 | $0.30 | $0.00 | ||
| Q1 25 | $-0.13 | $-0.05 | ||
| Q4 24 | $-0.25 | $0.10 | ||
| Q3 24 | $0.39 | $0.03 | ||
| Q2 24 | $0.00 | $-0.03 | ||
| Q1 24 | $1.27 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.9M | $14.7M |
| Total DebtLower is stronger | $15.6M | — |
| Stockholders' EquityBook value | $11.9M | $48.2M |
| Total Assets | $66.7M | $82.3M |
| Debt / EquityLower = less leverage | 1.31× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.9M | $14.7M | ||
| Q3 25 | $4.3M | $13.6M | ||
| Q2 25 | $26.1M | $17.9M | ||
| Q1 25 | $1.1M | $19.5M | ||
| Q4 24 | $825.0K | $19.8M | ||
| Q3 24 | $828.0K | $27.4M | ||
| Q2 24 | $1.7M | $23.4M | ||
| Q1 24 | $1.1M | — |
| Q4 25 | $15.6M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $41.2M | — | ||
| Q3 24 | $10.3M | — | ||
| Q2 24 | $15.7M | — | ||
| Q1 24 | $15.1M | — |
| Q4 25 | $11.9M | $48.2M | ||
| Q3 25 | $9.2M | $52.9M | ||
| Q2 25 | $414.0K | $49.9M | ||
| Q1 25 | $-11.6M | $45.2M | ||
| Q4 24 | $-9.0M | $43.2M | ||
| Q3 24 | $-1.4M | $32.4M | ||
| Q2 24 | $-44.7M | $28.6M | ||
| Q1 24 | $-61.7M | — |
| Q4 25 | $66.7M | $82.3M | ||
| Q3 25 | $66.8M | $82.3M | ||
| Q2 25 | $89.2M | $78.5M | ||
| Q1 25 | $56.7M | $73.9M | ||
| Q4 24 | $61.2M | $73.4M | ||
| Q3 24 | $66.5M | $61.6M | ||
| Q2 24 | $65.9M | $91.5M | ||
| Q1 24 | $67.8M | — |
| Q4 25 | 1.31× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-4.3M | $2.0M |
| Free Cash FlowOCF − Capex | $-4.3M | $1.6M |
| FCF MarginFCF / Revenue | -66.0% | 17.8% |
| Capex IntensityCapex / Revenue | 0.3% | 4.4% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-13.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-4.3M | $2.0M | ||
| Q3 25 | $-13.3M | $-3.7M | ||
| Q2 25 | $-7.9M | $-5.2M | ||
| Q1 25 | $945.0K | $-5.1M | ||
| Q4 24 | $-3.8M | $4.0M | ||
| Q3 24 | $-2.4M | $4.1M | ||
| Q2 24 | $-2.6M | $-3.6M | ||
| Q1 24 | $-3.8M | — |
| Q4 25 | $-4.3M | $1.6M | ||
| Q3 25 | $-13.4M | $-4.2M | ||
| Q2 25 | — | $-5.7M | ||
| Q1 25 | $853.0K | $-5.4M | ||
| Q4 24 | $-3.8M | $3.6M | ||
| Q3 24 | $-2.4M | $4.0M | ||
| Q2 24 | $-2.6M | $-3.8M | ||
| Q1 24 | $-3.8M | — |
| Q4 25 | -66.0% | 17.8% | ||
| Q3 25 | -329.6% | -23.7% | ||
| Q2 25 | — | -36.2% | ||
| Q1 25 | 49.9% | -53.0% | ||
| Q4 24 | -278.7% | 19.6% | ||
| Q3 24 | -114.9% | 22.4% | ||
| Q2 24 | -145.6% | -28.1% | ||
| Q1 24 | -248.8% | — |
| Q4 25 | 0.3% | 4.4% | ||
| Q3 25 | 1.0% | 2.8% | ||
| Q2 25 | 0.0% | 2.8% | ||
| Q1 25 | 5.4% | 3.0% | ||
| Q4 24 | 0.1% | 2.3% | ||
| Q3 24 | 0.2% | 0.5% | ||
| Q2 24 | 0.1% | 1.3% | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | -1.58× | ||
| Q2 25 | -0.31× | -31.91× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.61× | ||
| Q3 24 | -0.06× | 1.27× | ||
| Q2 24 | -0.33× | — | ||
| Q1 24 | -0.03× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FBYD
Segment breakdown not available.
PLX
| Products | $8.7M | 95% |
| Other | $428.0K | 5% |
